关键词

PD-1 单抗 肝损伤 过敏 免疫 人源化单抗

 

#今日行业热点#

①Lanect子刊：Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study

单药PD-1单抗sintilimab用于局部晚期直肠癌患者的有效性和可耐受性分析

DOI :10.1016/S2468-1253(22)00439-3

 

②Journal of Thoracic Oncology：Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients with Resectable Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial

卡曲瑞珠单抗（一种抗PD-1抗体）联合阿帕替尼用于可切除晚期非小细胞肺癌（NSCLC）的II期临床试验分析

DOI :10.1016/j.jtho.2023.02.019

 

③Journal of Hepatology：Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury

干扰素诱导的IL-10在慢性肝损伤期间驱动全身T细胞功能障碍

DOI :10.1016/j.jhep.2023.02.026

 

④Cell子刊：LMAN1 is a receptor for house dust mite allergens

过敏原识别过程新靶点——LMAN1是室内尘螨过敏原的受体

DOI :10.1016/j.celrep.2023.112208

 

⑤Nature Communications：CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy

CDK4/6抑制触发ICAM1驱动的免疫应答，并使LKB1突变肺癌对免疫治疗增敏

DOI :10.1038/s41467-023-36892-4

 

⑥Cell子刊：Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade

肿瘤中纤维细胞簇的鉴定揭示了PD-L1阻断在抗肿瘤免疫中的作用

DOI :10.1016/j.celrep.2023.112162

 

⑦人源化抗PD-L1单克隆抗体阿得贝利单抗获批，成为我国首个获批小细胞肺癌适应症的自主研发PD-L1抑制剂

 

⑧一种用于杜氏肌营养不良症(DMD)的“first-in-class”新药Vamorolone在英国MHRA提交上市许可申请

⑨一种潜在的“best-in-class”、高亲和力、IgG1亚型的全人源单克隆抗体Cosibelimab用于皮肤鳞状细胞癌（cSCC）的上市申请获FDA受理

 

⑩北京大学肿瘤医院领衔研发的一款基于重组人源化抗体获得的靶向CLDN18.2免疫PET探针用于胃肠道肿瘤无创成像的研究发表相关研究数据，成果显著

 

科学探索的世界充满挑战，AtaGenix致敬每一位拓荒者，更致力于成为您信赖的合作伙伴！